CGRP/SP–Piezo2 Axis in Trigeminal Neuralgia

Trigeminal neuralgia (TN) is defined by brief, severe orofacial pain that can be triggered by otherwise innocuous mechanical stimulation. Although compression at the trigeminal root entry zone is a frequent clinical association, the molecular events connecting compression with persistent mechanical allodynia remain incompletely resolved. The study by Liao and colleagues in Cellular & Molecular Biology Letters addresses this gap by connecting neuroinflammation, calcium signaling, neuropeptide release, and mechanotransduction in a rat model of TN. The full report is available through the reference study.

Study Background and Research Question

TN is commonly treated with surgery or sodium-channel inhibitors such as carbamazepine, but these approaches do not fully explain or eliminate the underlying sensory abnormality. A major unresolved question is why light facial contact becomes painful after trigeminal root compression. Earlier work implicated inflammatory signaling in the trigeminal ganglion (TG), while studies of sensory biology identified Piezo2 as a mechanosensitive ion channel involved in touch and proprioception. The relationship between these two fields—neuroinflammation and pathological mechanosensitivity—was not well established.

Liao et al. therefore asked whether chronic compression of the trigeminal nerve root entry zone produces an inflammatory signaling environment that changes Piezo2-dependent sensory processing. They focused on the interaction between trigeminal neurons and Merkel cells in the whisker pad, examining whether CGRP and substance P (SP) act with Piezo2 to amplify mechanical sensitivity. The study also tested whether intracellular Ca2+ signaling and downstream protein kinases provide the molecular link between extracellular inflammatory cues and altered mechanotransduction.

Key Innovation from the Reference Study

The central innovation is a mechanistic model in which neuroinflammation is not treated as a parallel consequence of TN, but as a prerequisite condition for peripheral sensitization. The authors describe a Ca2+–CGRP/SP–Piezo2 positive-feedback loop along the TG neuron–Merkel cell axis. In this model, inflammatory or purinergic stimulation increases CGRP and SP signaling, elevates Piezo2 expression, and enhances the ability of peripheral cells to respond to mechanical input. Piezo2-associated depolarization and Ca2+ influx can then reinforce intracellular signaling, potentially sustaining the sensitized state.

This framework is notable because it integrates several biological levels. At the tissue level, trigeminal root compression is associated with orofacial mechanical allodynia. At the cellular level, Piezo2, the CGRP receptor complex CLR–RAMP1, and the SP receptor NK1R are co-expressed in rat Merkel cells. At the signaling level, PKC, cAMP, ERK1/2, and p38 MAPK are positioned between extracellular ATP and transcriptional changes. The resulting model is more specific than a general statement that inflammation contributes to neuropathic pain: it proposes a defined receptor, ion-channel, neuropeptide, and kinase relationship.

Methods and Experimental Design Insights

The experimental design combines an in vivo compression model with compartment-specific molecular perturbation and cell-based mechanistic experiments. Chronic compression of the trigeminal root entry zone was used to generate a TN-like phenotype in rats. Mechanical sensitivity was then evaluated alongside molecular measurements in the TG and whisker pad, allowing the researchers to distinguish ganglion-level changes from changes in the peripheral target tissue.

A second strength was the use of intervention logic rather than expression profiling alone. The investigators manipulated cAMP signaling in the whisker pad and used Piezo2 knockdown in both the TG and whisker pad. They also challenged cells with extracellular ATP to determine whether purinergic stimulation could induce CGRP, SP, and Piezo2 through Ca2+-dependent kinase pathways. These complementary experiments help test directionality: whether a candidate pathway is merely associated with allodynia or is necessary for maintaining it.

Protocol Parameters

• Compression model: The reference study used chronic compression of the trigeminal root entry zone to reproduce a TN-like mechanical allodynia phenotype; this model should be interpreted as a mechanistic animal model rather than a complete representation of human TN.
• Compartment-specific sampling: Analyze the TG and whisker pad separately because the study assigns distinct but connected roles to trigeminal neurons and peripheral Merkel cells.
• cAMP perturbation: The authors tested inhibition of cAMP signaling in the whisker pad and used dibutyryl cAMP, or db cAMP, to challenge the pathway. These manipulations are useful for assessing whether cAMP activity is upstream of the observed sensory phenotype.
• Piezo2 loss-of-function design: Piezo2 knockdown in both the TG and whisker pad was used to evaluate whether channel expression is required for cAMP-associated allodynia, rather than simply correlated with it.
• ATP-to-transcription arm: In vitro extracellular ATP stimulation was paired with measurements of CGRP, SP, and Piezo2 expression, with attention to Ca2+-dependent ERK1/2 and p38 MAPK signaling and the transcription factors implicated by the study.
• Interpretation controls: As a workflow recommendation, pair behavioral measurements with localization, knockdown efficiency, and pathway readouts. This helps separate altered nociceptor excitability from changes in peripheral mechanosensory-cell signaling.

The study’s design also illustrates why anatomical localization matters. A treatment that changes TG expression may not have the same functional effect as one that acts in the whisker pad. The finding that both sites contribute to the phenotype argues for mapping the direction of signaling across the neuron–Merkel cell interface instead of assuming that all relevant events occur within the ganglion.

Core Findings and Why They Matter

1. Root compression produces a neuroinflammatory, mechanosensory phenotype

Chronic trigeminal root compression was associated with mechanical allodynia and increased expression of Piezo2, CGRP, and SP-related signaling components in the TG and whisker pad. According to the reported findings, this response provides a molecular bridge between the initiating lesion and abnormal sensitivity to facial touch.

2. Merkel cells may be an active peripheral signaling node

The co-expression of Piezo2, CLR–RAMP1, and NK1R on rat Merkel cells supports the idea that these cells can integrate mechanical and neuropeptide signals. Merkel cells are therefore presented not only as passive touch-associated cells but also as a potential peripheral amplifier of trigeminal sensitization. This observation is particularly important for experimental designs that measure only TG neurons, because it suggests that peripheral target tissues may preserve or intensify the pathological signal.

3. PKC and cAMP signaling are functionally connected to allodynia

The authors place PKC upstream of increased Piezo2, CGRP, and SP expression in the TG and whisker pad. Inhibition of cAMP signaling in the whisker pad alleviated mechanical allodynia, whereas db cAMP induced an allodynic response that was significantly reversed by Piezo2 knockdown in both examined compartments. These results support a functional relationship between second-messenger signaling and mechanosensitive-channel expression.

4. Extracellular ATP activates Ca2+-dependent kinase pathways

In vitro, extracellular ATP increased CGRP and SP expression and induced Piezo2 through Ca2+-dependent ERK1/2 and p38 MAPK cascades. The involvement of specific transcription factors provides an additional mechanistic layer: ATP is not simply producing rapid excitability, but can also alter gene expression associated with sensory amplification. This finding helps explain how a transient inflammatory environment might contribute to a more persistent change in mechanical responsiveness.

Together, these observations support a feed-forward model rather than a single linear pathway. Compression promotes inflammatory signaling; inflammatory and purinergic cues elevate neuropeptide and Piezo2 expression; Piezo2-mediated Ca2+ entry and downstream kinase activity then reinforce the sensitized state. The study does not establish that every component is equally dominant at every stage of TN, but it provides a testable architecture for future intervention studies.

Comparison with Existing Internal Articles

The available internal articles focus on a different biological application of YC-1. YC-1: A Causal Probe for Hypoxia Research presents YC-1 as a pharmacological tool for separating hypoxia signaling, soluble guanylyl cyclase activity, mitochondrial quality control, and cell fate. Meanwhile, YC-1: Soluble Guanylyl Cyclase Activator for Cancer Research emphasizes cGMP-related studies alongside inhibition of hypoxia-inducible factor 1 transcriptional activity, tumor angiogenesis inhibition, and apoptosis and cancer biology research.

These resources can help researchers distinguish two experimental contexts. The Liao et al. paper is a neuropathic-pain study centered on Ca2+, PKC, CGRP, SP, and Piezo2; it does not test YC-1, HIF-1α, or sGC signaling. The internal articles instead address hypoxia and cancer research, where YC-1 may be used as a pathway probe. Consequently, the reference findings should not be interpreted as evidence that YC-1 modulates the CGRP/SP–Piezo2 axis.

Why this cross-domain matters, maturity, and limitations

The comparison is useful because it prevents mechanistic overextension. Both research areas use pharmacological and molecular perturbations to dissect complex signaling networks, but the biological endpoints differ substantially: mechanical allodynia in the TN model versus hypoxia responses, vascular biology, or cancer-cell fate in YC-1 studies. The cross-domain connection is therefore methodological rather than therapeutic. Any attempt to test a hypoxia or sGC compound in a trigeminal pain model would require new dose-finding, target-engagement, behavioral, and tissue-specific validation. At present, the cited TN study supports the Ca2+–CGRP/SP–Piezo2 model, not a role for YC-1 in that mechanism.

Limitations and Transferability

Several limitations should guide interpretation. First, the findings are based on a rat compression model and rat Merkel-cell biology. Human TN includes heterogeneous causes, including vascular compression, demyelination, and secondary disease, so the relative importance of the TG neuron–Merkel cell axis may vary among patients. Second, knockdown experiments establish an important role for Piezo2 but do not fully resolve whether altered channel abundance, trafficking, gating, or cellular distribution is the dominant change.

Third, the study identifies a Ca2+-dependent ERK1/2 and p38 MAPK route and implicates transcriptional regulation, but the temporal sequence of all events remains to be determined. For example, it will be important to distinguish early ATP-driven signaling from later maintenance of channel and neuropeptide expression. Finally, behavioral improvement after pathway manipulation demonstrates biological relevance in the model, but it does not by itself establish clinical efficacy or define a safe therapeutic window.

Future work should therefore test the proposed loop in human-relevant tissues, clarify the contribution of each cellular compartment, and determine whether the same pathway persists during initiation and maintenance phases of TN. These directions follow directly from the reference study and do not require assuming that mechanisms established in hypoxia or cancer research apply to trigeminal pain.

Research Support Resources

For researchers developing related small-molecule pathway workflows outside the TN mechanism, YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol (SKU B7641) can support studies of sGC and hypoxia-associated signaling. The product information describes YC-1 as a crystalline sGC activator and HIF-1α pathway probe with reported purity above 98%; it should be used with appropriate vehicle, target-engagement, and pathway-specific controls, and it should not be treated as a validated substitute for the genetic and signaling perturbations used in the reference TN study.